Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Molecular Viewer

By Drug Discovery Trends Editor | June 25, 2010

cressetCresset has announced the release of FieldView, its powerful new molecular Fields visualizer. FieldView is a molecular viewer/editor designed to create, modify, view and compare molecules along with their associated Field patterns and physicochemical properties. This provides a richer more informative view of how molecules behave in biological systems.

“The release of a free version of FieldView is a major milestone for Cresset,” said Rob Scoffin, Chief Executive Officer of Cresset. “We want to bring the benefits of using molecular Fields to the widest possible audience, and the release of FieldView aims to provide anyone interested in chemistry with new insights into the properties of their molecules that they cannot get from any other tool.”

FieldView provides molecular editing tools that allow the creation, cloning and modification of molecules and chemical series. Up to 10,000 compounds can be loaded and displayed with their molecular Fields either individually, overlaid, or side-by-side. Generating a wide range of physicochemical properties, FieldView allows user-defined filtering of the structures to find and display those with the specific mix of desired properties.

FieldView automatically converts small molecules loaded in 2D from SDF or MOL2 files into minimized 3D conformations with their associated Fields. It can also visualize results from any of Cresset’s other Field based tools, as well those saved in Cresset’s native XED file format.

“By making the tool freely available, we want to encourage all chemists – from students starting their education through to seasoned drug discovery professionals – to take a new look at the activity and properties of their molecules and increase their understanding of why and how compounds have their specific effects” commented Andy Vinter, Founder and Chief Scientific Officer of Cresset.

For further information and to download a free copy, please visit here.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE